Market News

Latest financial and economic news and analysis

Newsfile Corp News Agency
1 weeks ago•Newsfile Corp
Stocks Medium Importance Neutral
ROSEN, A LEADING NATIONAL FIRM, Encourages Park Ha Biological Technology Co., Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PHH, BYAH

ROSEN, A LEADING NATIONAL FIRM, Encourages Park Ha Biological Technology Co., Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PHH, BYAH

New York, New York--(Newsfile Corp. - August 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH) (NASDAQ: BYAH) between December 27, 2024 and July 8, 2025, inclusive (the "Class Period").

Related Symbols 1
PHH PHH
Source: Newsfile Corp
Visit Source
0 0 0
Read More
Comment
Newsfile Corp News Agency
1 weeks ago•Newsfile Corp
Stocks Medium Importance Neutral
Lode Gold Completes Full Repayment of Fremont Gold Mine Property Secured Loan Ahead of Schedule

Lode Gold Completes Full Repayment of Fremont Gold Mine Property Secured Loan Ahead of Schedule

Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - Lode Gold Resources Inc. (TSXV: LOD) (OTCQB: LODFF) ("Lode Gold" or the "Company") is pleased to announce the full repayment of subsidiary Fremont Gold Mining LLC's long-term senior debt ("Secured Loan") secured by the Fremont Gold Mine property ("Fremont Property"), well ahead of the Secured Loan's scheduled maturity in 2028. With the repayment of approximately US$3.6 million of principal and accrued interest, the Fremont Property's pledging as security will be released, and Lode Gold and its subsidiaries will no longer have any loan obligations.

Related Symbols 1
LOD LOD
Source: Newsfile Corp
Visit Source
0 0 0
Read More
Comment
Zacks Investment Research News Agency
1 weeks ago•Zacks Investment Research
Stocks Medium Importance Neutral
Travere Therapeutics (TVTX) Reports Q2 Loss, Beats Revenue Estimates

Travere Therapeutics (TVTX) Reports Q2 Loss, Beats Revenue Estimates

Travere Therapeutics (TVTX) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.14 per share a year ago.

Related Symbols 1
TVTX TVTX
Source: Zacks Investment Research
Visit Source
0 0 0
Read More
Comment
Zacks Investment Research News Agency
1 weeks ago•Zacks Investment Research
Stocks Medium Importance Neutral
Gilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates

Gilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates

Gilead Sciences (GILD) came out with a quarterly loss of $6.75 per share versus the Zacks Consensus Estimate of a loss of $7.07. This compares to earnings of $2.01 per share a year ago.

Related Symbols 1
GILD GILD
Source: Zacks Investment Research
Visit Source
0 0 0
Read More
Comment
Zacks Investment Research News Agency
1 weeks ago•Zacks Investment Research
Stocks Medium Importance Neutral
Allegiant Travel (ALGT) Q2 Earnings Beat Estimates

Allegiant Travel (ALGT) Q2 Earnings Beat Estimates

Allegiant Travel (ALGT) came out with quarterly earnings of $2.19 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.23 per share a year ago.

Related Symbols 1
ALGT ALGT
Source: Zacks Investment Research
Visit Source
0 0 0
Read More
Comment
Zacks Investment Research News Agency
1 weeks ago•Zacks Investment Research
Stocks Medium Importance Neutral
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

Personalis (PSNL) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.23 per share a year ago.

Related Symbols 1
PSNL PSNL
Source: Zacks Investment Research
Visit Source
Special Offer LiteFinance Start Trading
0 0 0
Read More
Comment
Zacks Investment Research News Agency
1 weeks ago•Zacks Investment Research
Stocks Medium Importance Neutral
Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates

Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates

Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.88 per share, missing the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $3.28 per share a year ago.

Related Symbols 1
RIGL RIGL
Source: Zacks Investment Research
Visit Source
0 0 0
Read More
Comment
Zacks Investment Research News Agency
1 weeks ago•Zacks Investment Research
Stocks Medium Importance Neutral
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.83 per share a year ago.

Related Symbols 1
SNDX SNDX
Source: Zacks Investment Research
Visit Source
0 0 0
Read More
Comment
Newsfile Corp News Agency
1 weeks ago•Newsfile Corp
Stocks Medium Importance Neutral
DelphX Arranges Non-Brokered Unit Private Placement

DelphX Arranges Non-Brokered Unit Private Placement

Toronto, Ontario and New York, New York--(Newsfile Corp. - August 4, 2026) - DelphX Capital Markets Inc. (TSXV: DELX) (OTCQB: DPXCF) ("DelphX" or the "Company") Non-brokered private placement DelphX Capital Markets Inc. ("DelphX" or the "Company") arranges that it is revising the unit private placement component of the non-brokered financing previously announced on July 20, 2026. As disclosed in the Company's July 20, 2026 news release titled "DelphX Announces Non-Brokered Unit Private Placement and Convertible Debenture Financing," the previously announced financing included a unit private placement and a non-brokered private placement of convertible debentures.

Related Symbols 1
UNTC UNTC
Source: Newsfile Corp
Visit Source
Special Offer LiteFinance Start Trading
0 0 0
Read More
Comment